Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (apre una nuova finestra)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Fonte‎: Hemoglobin 2014;38(1):44-8.

Indicizzato‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (apre una nuova finestra)

Hydroxyurea in thalassemia intermedia--a promising therapy. (apre una nuova finestra)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Fonte‎: Ann Hematol 2005;84(7):441-6.

Indicizzato‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (apre una nuova finestra)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (apre una nuova finestra)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Fonte‎: J Clin Pathol 2010;63(2):147-50.

Indicizzato‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (apre una nuova finestra)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (apre una nuova finestra)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Fonte‎: Eur J Haematol 2009;82(3):213-8.

Indicizzato‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (apre una nuova finestra)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (apre una nuova finestra)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Fonte‎: Eur J Haematol 2010;84(1):52-8.

Indicizzato‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (apre una nuova finestra)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (apre una nuova finestra)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Fonte‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indicizzato‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (apre una nuova finestra)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (apre una nuova finestra)

Perrine SP.

Fonte‎: Pediatr Ann 2008;37(5):339-46.

Indicizzato‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (apre una nuova finestra)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (apre una nuova finestra)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Fonte‎: Ann N Y Acad Sci 2005;1054:250-6.

Indicizzato‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (apre una nuova finestra)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (apre una nuova finestra)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Fonte‎: Acta Haematol 2004;111(4):189-95.

Indicizzato‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (apre una nuova finestra)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (apre una nuova finestra)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Fonte‎: Blood Purif 2004;22(5):453-60.

Indicizzato‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (apre una nuova finestra)

The role of recombinant human erythropoietin in the treatment of thalassemia. (apre una nuova finestra)

Rachmilewitz EA, Aker M.

Fonte‎: Ann N Y Acad Sci 1998;850:129-38.

Indicizzato‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (apre una nuova finestra)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (apre una nuova finestra)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Fonte‎: Br J Haematol 2011;154(2):281-4.

Indicizzato‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (apre una nuova finestra)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (apre una nuova finestra)

Thein SL.

Fonte‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indicizzato‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (apre una nuova finestra)